CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $22.51M, above the global median of $16.24M
- PositionProfit margin is 104.3%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
877.45MUSDvs all stocks (USD)
Trailing P/E
7.59xvs Biotechnology peers
Revenue (TTM)
109.78MUSDvs all stocks (USD)
Profit Margin
104.34%vs Biotechnology peers
Beta
0.1730xvs all stocks
52-Week Change
49.16%vs all stocks
Market Capitalization
877.45MUSDvs all stocks (USD)
Enterprise Value
518.63MUSDvs all stocks (USD)
Trailing P/E
7.59xvs Biotechnology peers
Forward P/E
21.16xvs Biotechnology peers
PEG Ratio
-0.1206xvs Biotechnology peers
Price to Sales (TTM)
7.99xvs Biotechnology peers
Price to Book (MRQ)
3.00xvs Biotechnology peers
Enterprise to Revenue
4.72xvs Biotechnology peers
Enterprise to EBITDA
78.87xvs Biotechnology peers
Profit Margin
104.34%vs Biotechnology peers
Operating Margin
-33.05%vs Biotechnology peers
Return on Assets (TTM)
0.76%vs Biotechnology peers
Return on Equity (TTM)
50.17%vs Biotechnology peers
Revenue (TTM)
109.78MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.17USDUpdated Jul 19, 2026Quarterly Revenue Growth
15.00%vs Biotechnology peers
Gross Profit (TTM)
77.98MUSDvs all stocks (USD)
EBITDA (TTM)
59.38MUSDvs all stocks (USD)
Net Income (TTM)
114.54MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.02%vs Biotechnology peers
Operating Cash Flow (TTM)
268.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
22.51MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
107.46MUSDFY2025 · Dec 31, 2025Operating Income
-3.60MUSDvs all stocks (USD)
Pre-tax Income
129.25MUSDFY2025 · Dec 31, 2025Income Tax Expense
23.35MUSDFY2025 · Dec 31, 2025Net Income
105.89MUSDFY2025 · Dec 31, 2025EBIT
131.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
59.38MUSDFY2025 · Dec 31, 2025Research & Development
37.41MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
73.65MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.46MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.10USDFY2025 · Dec 31, 2025EPS (Diluted)
2.06USDFY2025 · Dec 31, 2025Basic Shares Outstanding
50.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
50.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
105.89MUSDFY2025 · Dec 31, 2025Operating Cash Flow
237.78MUSDFY2025 · Dec 31, 2025Free Cash Flow
237.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
168.64MUSDFY2025 · Dec 31, 2025Income Tax Paid
27.88MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
105.89MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.81MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-11.52MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.48MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.37MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.10MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
326.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
146.52MUSDFY2025 · Dec 31, 2025Capital Expenditures
-42.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-248.22MUSDFY2025 · Dec 31, 2025Sale of Investments
142.97MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-105.28MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-4.03MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.01MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.51MSharesUpdated Jul 19, 2026Float Shares
24.15MSharesUpdated Jul 19, 2026Shares Short
4.50MSharesUpdated Jul 19, 2026Short Ratio
6.31daysvs all stocks
Short % of Shares Outstanding
13.88%vs all stocks
% Held by Insiders
4.68%vs all stocks
% Held by Institutions
98.22%vs all stocks
Total Cash (MRQ)
394.67MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.66USDUpdated Jul 19, 2026Total Debt (MRQ)
40.50MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1394xvs Biotechnology peers
Current Ratio (MRQ)
13.14xvs Biotechnology peers
Book Value per Share (MRQ)
5.64USDUpdated Jul 19, 2026Total Assets
485.57MUSDvs all stocks (USD)
Total Current Assets
418.46MUSDFY2025 · Dec 31, 2025Total Liabilities
188.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
67.11MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
150.54MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
167.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
147.55MUSDFY2025 · Dec 31, 2025Accounts Receivable
45.54MUSDFY2025 · Dec 31, 2025Accounts Payable
2.57MUSDFY2025 · Dec 31, 2025Short-term Debt
10.95MUSDFY2025 · Dec 31, 2025Long-term Debt
31.76MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
33.11MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-859.63MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
296.72MUSDvs all stocks (USD)
52-Week Low
10.82USDUpdated Jul 19, 202652-Week High
21.03USDUpdated Jul 19, 202652-Week Change
49.16%vs all stocks
Beta
0.1730xvs all stocks
50-Day MA
16.64USDUpdated Jul 19, 2026200-Day MA
16.93USDUpdated Jul 19, 2026Avg 10-Day Volume
603.88KSharesUpdated Jul 19, 2026Avg 30-Day Volume
747.63KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
2.23USDUpdated Jul 19, 2026Other Income / Expense
125.14MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 104.3%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 1.04Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 50.2%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.50Industry median: -0.22Industry P95: 0.23Peers compared: 261
Financial Health
Altman Z-Score 2.37: grey zoneSignificant
Altman Z-Score: 2.37
High structural barrier to entryNotable
Barrier to Entry: 3.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $22.51M, above the global median of $16.24MNotable
Levered free cash flow (USD): 22,506,500Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Shentong Metro Co., Ltd.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt
Harmony Biosciences Holdings, Inc.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt
M&A Research Institute Holdings, Inc.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt